Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

59 Views

Physician

Resident

NewPractitioner

Session: GU: Organ Preservation and Personalization: Advancing Paradigms for Prostate, Bladder, and Kidney Cancer

1 - Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer: Current State of the Art

Friday, March 15, 2024

2:45 PM - 4:15 PM ET

Location: Grand Ballroom VI-VIII

Speaker(s)

Jason A. Efstathiou, MD, DPhil (he/him/his)

Professor
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School
Boston, Massachusetts, United States

Disclosure(s): Angiodynamics: Consultant/Advisory Board (Terminated); Astellas Pharm: Honoraria (Terminated); Blue Earth Diagnostics: Consultant (Ongoing); Boston Scientific: Consultant (Ongoing); Elekta, Inc.: Honoraria (Terminated); IBA: Honoraria (Terminated); Lantheus: Consultant (Ongoing)

PDF Slides

Disclosure(s):

Jason A. Efstathiou, MD, DPhil: Angiodynamics: Consultant/Advisory Board (Terminated); Astellas Pharm: Honoraria (Terminated); Blue Earth Diagnostics: Consultant (Ongoing); Boston Scientific: Consultant (Ongoing); Elekta, Inc.: Honoraria (Terminated); IBA: Honoraria (Terminated); Lantheus: Consultant (Ongoing)

Learning Objectives:

Apply data/evidence supporting trimodality therapy (TMT) as a proven alternative to cystectomy for selected patients
Describe advances in TMT including the potential for combining immunotherapy with TMT
Recognize clinical factors and biomarkers associated with outcomes